{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:11:33Z","timestamp":1790766693867,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS089076"],"award-info":[{"award-number":["R01 NS089076"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54 NS091046"],"award-info":[{"award-number":["U54 NS091046"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-throughput screening and gene signature analyses frequently identify lead therapeutic compounds with unknown modes of action (MoAs), and the resulting uncertainties can lead to the failure of clinical trials. We developed an approach for uncovering MoAs through an interpretable machine learning model of transcriptomics, epigenomics, metabolomics, and proteomics. Examining compounds with beneficial effects in models of Huntington\u2019s Disease, we found common MoAs for compounds with unrelated structures, connectivity scores, and binding targets. The approach also predicted highly divergent MoAs for two FDA-approved antihistamines. We experimentally validated these effects, demonstrating that one antihistamine activates autophagy, while the other targets bioenergetics. The use of multiple omics was essential, as some MoAs were virtually undetectable in specific assays. Our approach does not require reference compounds or large databases of experimental data in related systems and thus can be applied to the study of agents with uncharacterized MoAs and to rare or understudied diseases.<\/jats:p>","DOI":"10.1038\/s41598-020-57691-7","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:04:44Z","timestamp":1579691084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules"],"prefix":"10.1038","volume":"10","author":[{"given":"Natasha L.","family":"Patel-Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook T.","family":"Wassie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-8181","authenticated-orcid":false,"given":"Ernest","family":"Fraenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"57691_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cels.2018.03.012","volume":"6","author":"L Litichevskiy","year":"2018","unstructured":"Litichevskiy, L. et al. A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. Cell Syst. 6, 424\u201343.e7 (2018).","journal-title":"Cell Syst."},{"key":"57691_CR2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science (80-.). 313, 1929\u201335 (2006).","journal-title":"Science (80-.)."},{"key":"57691_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171, 1437\u201352.e17 (2017).","journal-title":"Cell"},{"key":"57691_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrd2898","volume":"8","author":"M Wehling","year":"2009","unstructured":"Wehling, M. Assessing the translatability of drug projects: What needs to be scored to predict success? Nat. Rev. Drug Discov. 8, 541\u20136 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"57691_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2018","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u201386 (2018).","journal-title":"Biostatistics"},{"key":"57691_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/iub.1697","volume":"70","author":"LB Tulloch","year":"2018","unstructured":"Tulloch, L. B. et al. Direct and indirect approaches to identify drug modes of action. IUBMB Life 70, 9\u201322 (2018).","journal-title":"IUBMB Life"},{"key":"57691_CR7","first-page":"7","volume":"13","author":"F Iorio","year":"2013","unstructured":"Iorio, F., Saez-Rodriguez, J. & Bernardo, D. di. Network based elucidation of drug response: From modulators to targets. BMC Syst. Biol. 13, 7\u2013139 (2013).","journal-title":"BMC Syst. Biol."},{"key":"57691_CR8","doi-asserted-by":"crossref","unstructured":"Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl. Med. 10 (2018).","DOI":"10.1126\/scitranslmed.aal3973"},{"key":"57691_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109\u201316 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"57691_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cell.2015.05.056","volume":"162","author":"JH Woo","year":"2015","unstructured":"Woo, J. H. et al. Elucidating Compound Mechanism of Action by Network Perturbation Analysis. Cell 162, 441\u201351 (2015).","journal-title":"Cell"},{"key":"57691_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/138620708783877753","volume":"11","author":"H Varma","year":"2008","unstructured":"Varma, H., Lo, D. & Stockwell, B. High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes. Comb. Chem. High Throughput Screen. 11, 238\u201348 (2008).","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"57691_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","volume":"556","author":"A Kumar","year":"2015","unstructured":"Kumar, A. et al. Huntington\u2019s disease: An update of therapeutic strategies. Gene. 556, 91\u20137 (2015).","journal-title":"Gene."},{"key":"57691_CR13","first-page":"65","volume":"5","author":"J Schulte","year":"2011","unstructured":"Schulte, J. & Littleton, J. T. The biological function of the Huntingtin protein and its relevance to Huntington\u2019s Disease pathology. Curr. Trends Neurol. 5, 65\u201378 (2011).","journal-title":"Curr. Trends Neurol."},{"key":"57691_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato, C., Valenza, M. & Cattaneo, E. Molecular Mechanisms and Potential Therapeutical Targets in Huntington\u2019s Disease. Physiol Rev 90, 905\u201381 (2010).","journal-title":"Physiol Rev"},{"key":"57691_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00353-6","volume":"8","author":"L Pirhaji","year":"2017","unstructured":"Pirhaji, L. et al. Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements. Nat. Commun. 8, 623 (2017).","journal-title":"Nat. Commun."},{"key":"57691_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coph.2018.08.006","volume":"42","author":"A Kedaigle","year":"2018","unstructured":"Kedaigle, A. & Fraenkel, E. Turning omics data into therapeutic insights. Curr. Opin. Pharmacol. 42, 95\u2013101 (2018).","journal-title":"Curr. Opin. Pharmacol."},{"key":"57691_CR17","doi-asserted-by":"crossref","unstructured":"Bates, G., Tabrizi, S. J. & Jones, L. Huntington\u2019s Disease. (Oxford University Press, 2014).","DOI":"10.1093\/med\/9780199929146.001.0001"},{"key":"57691_CR18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/hmg\/9.19.2799","volume":"9","author":"F Trettel","year":"2000","unstructured":"Trettel, F. et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799\u2013809 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"57691_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JHD-120033","volume":"1","author":"MR Sarantos","year":"2012","unstructured":"Sarantos, M. R., Papanikolaou, T., Ellerby, L. M. & Hughes, R. E. Pizotifen activates ERK and provides neuroprotection in vitro and in vivo in models of Huntington\u2019s disease. J. Huntingtons. Dis. 1, 195\u2013210 (2012).","journal-title":"J. Huntingtons. Dis."},{"key":"57691_CR20","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gkr320","volume":"39","author":"TWH Backman","year":"2011","unstructured":"Backman, T. W. H., Cao, Y. & Girke, T. ChemMine tools: An online service for analyzing and clustering small molecules. Nucleic Acids Res. 39, W486\u201391 (2011).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nmeth.3940","volume":"13","author":"L Pirhaji","year":"2016","unstructured":"Pirhaji, L. et al. Revealing disease-associated pathways by network integration of untargeted metabolomics. Nat. Methods 13, 770\u20136 (2016).","journal-title":"Nat. Methods"},{"key":"57691_CR22","doi-asserted-by":"publisher","first-page":"e1004879","DOI":"10.1371\/journal.pcbi.1004879","volume":"12","author":"N Tuncbag","year":"2016","unstructured":"Tuncbag, N. et al. Network-Based Interpretation of Diverse High-Throughput Datasets through the Omics Integrator Software Package. PLoS Comput. Biol. 12, e1004879 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"57691_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ng1966","volume":"39","author":"ND Heintzman","year":"2007","unstructured":"Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311\u20138 (2007).","journal-title":"Nat. Genet."},{"key":"57691_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","volume":"38","author":"DDO Martin","year":"2015","unstructured":"Martin, D. D. O., Ladha, S., Ehrnhoefer, D. E. & Hayden, M. R. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 38, 26\u201335 (2015).","journal-title":"Trends Neurosci."},{"key":"57691_CR25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4161\/auto.4600","volume":"3","author":"N Mizushima","year":"2007","unstructured":"Mizushima, N. & Yoshimori, T. How to interpret LC3 immunoblotting. Autophagy 3, 542\u20135 (2007).","journal-title":"Autophagy"},{"key":"57691_CR26","unstructured":"Kedaigle, A. et al. Bioenergetic deficits in Huntington\u2019s disease iPSC-derived neural cells and rescue with glycolytic metabolites. Hum. Mol. Genet. (2019)."},{"key":"57691_CR27","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","volume":"45","author":"A Gaulton","year":"2017","unstructured":"Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945\u201354 (2017).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR28","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u201361 (2013).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR29","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u201382 (2018).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR30","doi-asserted-by":"crossref","unstructured":"Hong, C. T., Chau, K. Y. & Schapira, A. H. V. Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Sci. Rep. 6 (2016).","DOI":"10.1038\/srep25344"},{"key":"57691_CR31","doi-asserted-by":"publisher","first-page":"35387","DOI":"10.1074\/jbc.M113.489237","volume":"288","author":"VM Gohil","year":"2013","unstructured":"Gohil, V. M. et al. Meclizine inhibits mitochondrial respiration through direct targeting of cytosolic phosphoethanolamine metabolism. J. Biol. Chem. 288, 35387\u201395 (2013).","journal-title":"J. Biol. Chem."},{"key":"57691_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2018.08.004","volume":"34","author":"TC Archer","year":"2018","unstructured":"Archer, T. C. et al. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 34, 396\u2013410.e8 (2018).","journal-title":"Cancer Cell"},{"key":"57691_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature22973","volume":"547","author":"PA Northcott","year":"2017","unstructured":"Northcott, P. A. et al. The whole-genome landscape of medulloblastoma subtypes. Nature 547, 311\u2013317 (2017).","journal-title":"Nature"},{"key":"57691_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1039\/C6IB00040A","volume":"8","author":"JL Wilson","year":"2016","unstructured":"Wilson, J. L. et al. Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integr. Biol. 8, 761\u2013774 (2016).","journal-title":"Integr. Biol."},{"key":"57691_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/ng.337","volume":"41","author":"E Yeger-Lotem","year":"2009","unstructured":"Yeger-Lotem, E. et al. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat. Genet. 41, 316\u2013323 (2009).","journal-title":"Nat. Genet."},{"key":"57691_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cels.2016.12.011","volume":"4","author":"V Khurana","year":"2017","unstructured":"Khurana, V. et al. Genome-Scale Networks Link Neurodegenerative Disease Genes to \u03b1-Synuclein through Specific Molecular Pathways. Cell Syst. 4, 157\u2013170.e14 (2017).","journal-title":"Cell Syst."},{"key":"57691_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u20135 (2012).","journal-title":"Nat. Methods"},{"key":"57691_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter, A. E. et al. CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. Genome. Biol. 7, R100 (2006).","journal-title":"Genome. Biol."},{"key":"57691_CR39","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u201320 (2014).","journal-title":"Bioinformatics"},{"key":"57691_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"57691_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"57691_CR42","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR43","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nbt.4072","volume":"36","author":"E Brunk","year":"2018","unstructured":"Brunk, E. et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat. Biotechnol. 36, 272\u201381 (2018).","journal-title":"Nat. Biotechnol."},{"key":"57691_CR44","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res. 46, D1074\u201382 (2018).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR45","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1021\/ac502040v","volume":"86","author":"GC McAlister","year":"2014","unstructured":"McAlister, G. C. et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150\u20138 (2014).","journal-title":"Anal. Chem."},{"key":"57691_CR46","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.cell.2014.04.028","volume":"157","author":"MP Weekes","year":"2014","unstructured":"Weekes, M. P. et al. Quantitative temporal viromics: An approach to investigate host-pathogen interaction. Cell 157, 1460\u201372 (2014).","journal-title":"Cell"},{"key":"57691_CR47","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2015","unstructured":"Hornbeck, P. V. et al. PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512\u201320 (2015).","journal-title":"Nucleic Acids Res."},{"key":"57691_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-405","volume":"9","author":"S Razick","year":"2008","unstructured":"Razick, S., Magklaras, G. & Donaldson, I. M. iRefIndex: A consolidated protein interaction database with provenance. BMC Bioinformatics 9, 405 (2008).","journal-title":"BMC Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57691-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:52:59Z","timestamp":1670305979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57691-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57691"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-57691-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"954"}}